Neurocrine Biosciences (NBIX) Total Liabilities (2010 - 2026)
Neurocrine Biosciences (NBIX) posted quarterly Total Liabilities of $1.7 billion for Q2 2026, up 39.31% year-over-year from $1.2 billion in Q2 2025, and up 11.12% on a QoQ basis from $1.5 billion in Q1 2026.
Neurocrine Biosciences (NBIX) Total Liabilities (2010 - 2026) Analysis & Trends
Neurocrine Biosciences has reported Total Liabilities for 17 years, with the latest figure at $1.7 billion in Q2 2026.
- Total Liabilities for Q2 2026 came in at $1.7 billion, up 39.31% year-over-year; the trailing twelve-month figure through Jun 2026 was $1.7 billion (up 39.31% YoY), and the FY2025 annual result was $1.4 billion, up 22.09% from the prior year.
- Total Liabilities grew to $1.7 billion in Q2 2026, from $1.5 billion in the prior quarter.
- Over five years, Total Liabilities peaked at $1.7 billion in Q2 2026 and troughed at $582.3 million in Q2 2022.
- A 5-year average of $993.1 million and a median of $932.8 million in 2023 frame the typical range for Total Liabilities.
- The widest annual swing landed in 2022, when Total Liabilities slipped 14.01%; it then soared 60.86% in 2024.
- A 5-year view of Total Liabilities shows it stood at $660.9 million in 2022, then surged by 54.24% to $1.0 billion in 2023, then grew by 10.75% to $1.1 billion in 2024, then rose by 22.09% to $1.4 billion in 2025, then advanced by 20.83% to $1.7 billion in 2026.
- Per Business Quant data, the three most recent Total Liabilities figures were $1.7 billion in Q2 2026, $1.5 billion in Q1 2026, and $1.4 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | -21.66 Bn |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn | 32.10 Bn |
| 3 | Zoetis | 31.79 Bn | 30.11 Bn | 1.05 Bn | 11.93 Bn |
| 4 | Takeda Pharmaceutical | 28.69 Bn | 22.89 Bn | 5.10 Bn | 50.85 Bn |
| 5 | United Therapeutics | 22.25 Bn | 19.58 Bn | 683.80 Mn | 819.80 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 20.78 Bn |
| 7 | Neurocrine Biosciences | 15.58 Bn | 15.19 Bn | 935.80 Mn | 1.67 Bn |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn | 6.97 Bn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | 2.12 Bn |
| 10 | Alkermes | 8.15 Bn | 7.49 Bn | 397.90 Mn | 2.58 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.67 Bn |
| Mar 31, 2026 | 1.50 Bn |
| Dec 31, 2025 | 1.38 Bn |
| Sep 30, 2025 | 1.26 Bn |
| Jun 30, 2025 | 1.20 Bn |
| Mar 31, 2025 | 1.15 Bn |
| Dec 31, 2024 | 1.13 Bn |
| Sep 30, 2024 | 816.10 Mn |
| Jun 30, 2024 | 795.80 Mn |
| Mar 31, 2024 | 1.09 Bn |
| Dec 31, 2023 | 1.02 Bn |
| Sep 30, 2023 | 846.10 Mn |
| Jun 30, 2023 | 760.10 Mn |
| Mar 31, 2023 | 675.30 Mn |
| Dec 31, 2022 | 660.90 Mn |
| Sep 30, 2022 | 598.80 Mn |
| Jun 30, 2022 | 582.30 Mn |
| Mar 31, 2022 | 753.40 Mn |
| Dec 31, 2021 | 698.50 Mn |
| Sep 30, 2021 | 671.30 Mn |